Search Results - "Moik, M."

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 by Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic-Radisic, V., Balic, M., Eidtmann, H., Eiermann, W., Steger, G., Kwasny, W., Dubsky, P., Selim, U., Fitzal, F., Hochreiner, G., Wette, V., Sevelda, P., Ploner, F., Bartsch, R., Fesl, C., Greil, R.

“…These final results from ABCSG-12 confirm that twice-yearly ZOL safely enhances the efficacy of adjuvant endocrine therapy. Tamoxifen together with Goserelin…”
Get full text

Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial by Pfeiler, G, Stöger, H, Dubsky, P, Mlineritsch, B, Singer, C, Balic, M, Fitzal, F, Moik, M, Kwasny, W, Selim, U, Renner, K, Ploner, F, Steger, G G, Seifert, M, Hofbauer, F, Sandbichler, P, Samonigg, H, Jakesz, R, Greil, R, Fesl, C, Gnant, M

“…Background: There exists evidence that body mass index (BMI) impacts on the efficacy of aromatase inhibitors in patients with breast cancer. The relationship…”
Get full text

Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study by Greil, R, Moik, M, Reitsamer, R, Ressler, S, Stoll, M, Namberger, K, Menzel, C, Mlineritsch, B

“…Abstract Purpose To evaluate the triplet combination of bevacizumab, capecitabine and docetaxel (XTA) as neoadjuvant therapy for breast cancer. Experimental…”
Get full text

Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial by Gnant, M, Steger, G, Greil, R, Fitzal, F, Mlineritsch, B, Manfreda, D, Tausch, C, Balic, M, Dubsky, P, Moik, M, Thaler, J, Egle, D, Bjelic-Radisic, V, Selim, U, Exner, R, Singer, C, Melbinger-Zeinitzer, E, Haslbauer, F, Stöger, H, Helfgott, R, Sevelda, P, Trapl, H, Wette, V, Sölkner, L, Jakesz, R

“…Abstract Background: While extended adjuvant therapy with aromatase inhibitors (AI) after initial tamoxifen has been demonstrated to improve…”
Get full text

Efficacy of tamoxifen plus or minus aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial by Pfeiler, G, Stoger, H, Dubsky, P, Mlineritsch, B, Singer, C, Balic, M, Fitzal, F, Moik, M, Kwasny, W, Selim, U, Renner, K, Ploner, F, Steger, G G, Seifert, M, Hofbauer, F, Sandbichler, P, Samonigg, H, Jakesz, R, Greil, R, Fesl, C, Gnant, M

“…Background: There exists evidence that body mass index (BMI) impacts on the efficacy of aromatase inhibitors in patients with breast cancer. The relationship…”
Get full text

Efficacy of neoadjuvant bevacizumab (Av), capecitabine (X), and docetaxel (T) for invasive breast cancer (BC): Phase II result by Greil, R., Moik, M., Reitsamer, R., Ressler, S., Stoll, M., Namberger, K., Menzel, C., Mlineritsch, B.

“…Abstract only…”
Get full text

A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer by Riess, H., Helm, A., Niedergethmann, M., Schmidt-Wolf, I., Moik, M., Hammer, C., Zippel, K., Weigang-Köhler, K., Stauch, M., Oettle, H.

“…Abstract only…”
Get full text